Dr. Schaber will review recent progress relating to DOR's lead productorBec® and its unique value proposition, as well as DOR's otherbiotherapeutic and biodefense programs. The conference and Dr. Schaber'spresentation will take place in the Louis Room, 4th Floor at the New YorkPalace Hotel on 455 Madison Avenue in New York City. Following thepresentation, DOR management also will participate in a 10-minutequestion-and-answer session as well as in one-on-one meetings withinvestors and potential partners throughout the conference. Thepresentation will be webcast live and may be accessed by visitinghttp://www.wsw.com/webcast/rrshq14/dorb.ob/. The presentation will bearchived here and available for 90 days after the event. In addition, areplay of the webcast will be available on DOR BioPharma's website(www.dorbiopharma.com) for approximately 30 days following thepresentation.

Former President Bill Clinton will open Rodman's most expansive conferenceto date, with more than 550 growth companies presenting and over 3,500registered attendees from the medical, scientific and investmentcommunities. The categories of presentation include specialtypharmaceuticals, oncology, drug delivery, vaccines, autoimmune diseases,cardiovascular diseases, CNS, gene therapy, infectious diseases, andmedical devices.

About DOR BioPharma, Inc.

DOR BioPharma, Inc. (DOR) is a late-stage biopharmaceutical companydeveloping products to treat life-threatening side effects of cancertreatments and serious gastrointestinal diseases, and vaccines for certainbioterrorism agents. DOR's lead product, orBec® (oral beclomethasonedipropionate or BDP), is a potent, locally acting corticosteroid beingdeveloped for the treatment of gastrointestinal Graft-versus-Host disease(GI GVHD), a common and potentially life-threatening complication of bonemarrow transplantation. DOR filed a New Drug Application for orBec® withthe FDA for the treatment of acute GI GVHD and received a not approvableletter in which the FDA has requested data from a confirmatory Phase 3clinical trial to demonstrate the safety and efficacy of orBec®. orBec® iscurrently the subject of an NIH-supported, Phase 2, randomized,double-blind, placebo-controlled trial in the prevention of acute GVHD.Oral BDP may also have application in treating other gastrointestinaldisorders characterized by severe inflammation. Additionally, DOR has aLipid Polymer Micelle (LPM™) drug delivery technology for the oral deliveryof leuprolide for the treatment of prostate cancer and endometriosis.

Through its Biodefense Division, DOR is developing biomedicalcountermeasures pursuant to the Project BioShield Act of 2004. DOR'sbiodefense products in development are recombinant subunit vaccinesdesigned to protect against the lethal effects of exposure to ricin toxin,botulinum toxin and anthrax. DOR's ricin toxin vaccine, RiVax™, has beenshown to be well tolerated and immunogenic in a Phase 1 clinical trial innormal volunteers.

For further information regarding DOR BioPharma, Inc., please visit theCompany's website located at www.dorbiopharma.com.

This press release contains forward-looking statements that reflect DORBioPharma, Inc.'s current expectations about its future results,performance, prospects and opportunities. Statements that are nothistorical facts, such as "anticipates," "believes," "intends," or similarexpressions, are forward-looking statements. These statements are subjectto a number of risks, uncertainties and other factors that could causeactual events or results in future periods to differ materially from whatis expressed in, or implied by, these statements. DOR cannot assure youthat it will be able to successfully develop or commercialize productsbased on its technology, including orBec®, particularly in light of thesignificant uncertainty inherent in developing vaccines against bioterrorthreats, manufacturing and conducting preclinical and clinical trials ofvaccines, and obtaining regulatory approvals, that its cash expenditureswill not exceed projected levels, that it will be able to securepartnerships or obtain financing within the next six months to meetoperating expenses and to conduct its upcoming confirmatory Phase 3 trialof orBec®, that product development and commercialization efforts will notbe reduced or discontinued due to difficulties or delays in clinical trialsor due to lack of progress or positive results from research anddevelopment efforts, that it will be able to successfully obtain anyfurther grants and awards, maintain its existing grants which are subjectto performance, enter into any biodefense procurement contracts with the USGovernment or other countries, that the US Congress may not pass anylegislation that would provide additional funding for the Project BioShieldprogram, that it will be able to patent, register or protect its technologyfrom challenge and products from competition or maintain or expand itslicense agreements with its current licensors, or that its businessstrategy will be successful. Important factors which may affect the futureuse of orBec® for gastrointestinal GVHD include the risks that: the FDA'srequirement that DOR conduct additional clinical trials to demonstrate thesafety and efficacy of orBec® will take a significant amount of time andmoney to complete and positive results leading to regulatory approvalcannot be assumed; DOR is dependent on the expertise, effort, prioritiesand contractual obligations of third parties in the clinical trials,manufacturing, marketing, sales and distribution of its products; orBec®may not gain market acceptance if it is eventually approved by the FDA; andothers may develop technologies or products superior to orBec®. These andother factors are described from time to time in filings with theSecurities and Exchange Commission, including, but not limited to, DOR'smost recent reports on Forms 10-Q and 10-KSB. Unless required by law, DORassumes no obligation to update or revise any forward-looking statements asa result of new information, future events.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Company Contact:Evan MyrianthopoulosChief Financial Officer(609) 538-8200www.dorbiopharma.comDOR BioPharma, Inc.850 Bear Tavern Road, Suite 201Ewing, NJ 08628